Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-8400 in Dermatomyositis
NCT02612857Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- Nov 2015
- Primary completion
- May 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
A Phase 2 trial of bazlitoran in dermatomyositis (DM), sponsored by Aceragen, Inc.. Started Nov 2015; status: completed.
02
Drugs
bazlitoran
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT02612857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612857.